According to a new report by Polaris Market Research, the U.S. oncology based molecular diagnostics market was valued at USD 1.34 billion in 2024 and is projected to reach USD 2.29 billion by 2034, expanding at a CAGR of 5.5% over the forecast period. Growth is underpinned by rising cancer incidence, expanding adoption of personalized medicine, and accelerating use of next-generation...